GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001905823 | Lung | AAH | viral life cycle | 21/613 | 317/18723 | 1.85e-03 | 4.31e-02 | 21 |
GO:190331132 | Lung | MIAC | regulation of mRNA metabolic process | 45/967 | 288/18723 | 2.75e-11 | 4.70e-08 | 45 |
GO:004217633 | Lung | MIAC | regulation of protein catabolic process | 47/967 | 391/18723 | 6.27e-08 | 2.15e-05 | 47 |
GO:000989632 | Lung | MIAC | positive regulation of catabolic process | 54/967 | 492/18723 | 1.42e-07 | 3.64e-05 | 54 |
GO:003011122 | Lung | MIAC | regulation of Wnt signaling pathway | 41/967 | 328/18723 | 1.51e-07 | 3.69e-05 | 41 |
GO:001605531 | Lung | MIAC | Wnt signaling pathway | 50/967 | 444/18723 | 1.88e-07 | 4.02e-05 | 50 |
GO:019873831 | Lung | MIAC | cell-cell signaling by wnt | 50/967 | 446/18723 | 2.16e-07 | 4.11e-05 | 50 |
GO:000641733 | Lung | MIAC | regulation of translation | 51/967 | 468/18723 | 3.94e-07 | 6.52e-05 | 51 |
GO:003133132 | Lung | MIAC | positive regulation of cellular catabolic process | 46/967 | 427/18723 | 2.00e-06 | 2.44e-04 | 46 |
GO:004573232 | Lung | MIAC | positive regulation of protein catabolic process | 30/967 | 231/18723 | 3.16e-06 | 3.45e-04 | 30 |
GO:004348831 | Lung | MIAC | regulation of mRNA stability | 23/967 | 158/18723 | 6.62e-06 | 6.29e-04 | 23 |
GO:004348731 | Lung | MIAC | regulation of RNA stability | 24/967 | 170/18723 | 7.20e-06 | 6.53e-04 | 24 |
GO:001905833 | Lung | MIAC | viral life cycle | 36/967 | 317/18723 | 8.00e-06 | 7.07e-04 | 36 |
GO:00431293 | Lung | MIAC | surfactant homeostasis | 6/967 | 12/18723 | 1.32e-05 | 9.85e-04 | 6 |
GO:006101331 | Lung | MIAC | regulation of mRNA catabolic process | 23/967 | 166/18723 | 1.52e-05 | 1.07e-03 | 23 |
GO:000838023 | Lung | MIAC | RNA splicing | 44/967 | 434/18723 | 1.56e-05 | 1.07e-03 | 44 |
GO:000640231 | Lung | MIAC | mRNA catabolic process | 28/967 | 232/18723 | 2.65e-05 | 1.66e-03 | 28 |
GO:001657022 | Lung | MIAC | histone modification | 45/967 | 463/18723 | 3.58e-05 | 1.97e-03 | 45 |
GO:00488753 | Lung | MIAC | chemical homeostasis within a tissue | 6/967 | 14/18723 | 3.92e-05 | 2.08e-03 | 6 |
GO:00426922 | Lung | MIAC | muscle cell differentiation | 39/967 | 384/18723 | 4.51e-05 | 2.36e-03 | 39 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0002014 | Esophagus | ESCC | Citrate cycle (TCA cycle) | 27/4205 | 30/8465 | 3.48e-06 | 1.94e-05 | 9.95e-06 | 27 |
hsa0120023 | Esophagus | ESCC | Carbon metabolism | 79/4205 | 115/8465 | 2.50e-05 | 1.21e-04 | 6.22e-05 | 79 |
hsa0123023 | Esophagus | ESCC | Biosynthesis of amino acids | 49/4205 | 75/8465 | 4.35e-03 | 1.12e-02 | 5.74e-03 | 49 |
hsa0062023 | Esophagus | ESCC | Pyruvate metabolism | 32/4205 | 47/8465 | 8.11e-03 | 1.94e-02 | 9.94e-03 | 32 |
hsa0002015 | Esophagus | ESCC | Citrate cycle (TCA cycle) | 27/4205 | 30/8465 | 3.48e-06 | 1.94e-05 | 9.95e-06 | 27 |
hsa0120033 | Esophagus | ESCC | Carbon metabolism | 79/4205 | 115/8465 | 2.50e-05 | 1.21e-04 | 6.22e-05 | 79 |
hsa0123033 | Esophagus | ESCC | Biosynthesis of amino acids | 49/4205 | 75/8465 | 4.35e-03 | 1.12e-02 | 5.74e-03 | 49 |
hsa0062033 | Esophagus | ESCC | Pyruvate metabolism | 32/4205 | 47/8465 | 8.11e-03 | 1.94e-02 | 9.94e-03 | 32 |
hsa0120010 | Liver | NAFLD | Carbon metabolism | 26/1043 | 115/8465 | 1.39e-03 | 1.71e-02 | 1.38e-02 | 26 |
hsa0120011 | Liver | NAFLD | Carbon metabolism | 26/1043 | 115/8465 | 1.39e-03 | 1.71e-02 | 1.38e-02 | 26 |
hsa0120021 | Liver | Cirrhotic | Carbon metabolism | 64/2530 | 115/8465 | 6.37e-09 | 1.18e-07 | 7.26e-08 | 64 |
hsa006208 | Liver | Cirrhotic | Pyruvate metabolism | 29/2530 | 47/8465 | 5.90e-06 | 5.95e-05 | 3.67e-05 | 29 |
hsa0002010 | Liver | Cirrhotic | Citrate cycle (TCA cycle) | 21/2530 | 30/8465 | 6.56e-06 | 6.24e-05 | 3.84e-05 | 21 |
hsa012304 | Liver | Cirrhotic | Biosynthesis of amino acids | 35/2530 | 75/8465 | 1.54e-03 | 7.83e-03 | 4.83e-03 | 35 |
hsa0120031 | Liver | Cirrhotic | Carbon metabolism | 64/2530 | 115/8465 | 6.37e-09 | 1.18e-07 | 7.26e-08 | 64 |
hsa0062011 | Liver | Cirrhotic | Pyruvate metabolism | 29/2530 | 47/8465 | 5.90e-06 | 5.95e-05 | 3.67e-05 | 29 |
hsa0002011 | Liver | Cirrhotic | Citrate cycle (TCA cycle) | 21/2530 | 30/8465 | 6.56e-06 | 6.24e-05 | 3.84e-05 | 21 |
hsa0123011 | Liver | Cirrhotic | Biosynthesis of amino acids | 35/2530 | 75/8465 | 1.54e-03 | 7.83e-03 | 4.83e-03 | 35 |
hsa0120041 | Liver | HCC | Carbon metabolism | 89/4020 | 115/8465 | 3.92e-11 | 6.56e-10 | 3.65e-10 | 89 |
hsa0002021 | Liver | HCC | Citrate cycle (TCA cycle) | 28/4020 | 30/8465 | 1.08e-07 | 1.44e-06 | 8.02e-07 | 28 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PC | SNV | Missense_Mutation | novel | c.1378N>A | p.Ala460Thr | p.A460T | P11498 | protein_coding | deleterious(0.01) | benign(0.108) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PC | SNV | Missense_Mutation | novel | c.1726N>G | p.Ser576Ala | p.S576A | P11498 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AR-A256-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | PD |
PC | SNV | Missense_Mutation | | c.619N>C | p.Val207Leu | p.V207L | P11498 | protein_coding | deleterious(0.01) | possibly_damaging(0.822) | TCGA-B6-A0I6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
PC | SNV | Missense_Mutation | | c.584C>T | p.Ala195Val | p.A195V | P11498 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-B6-A0IB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
PC | SNV | Missense_Mutation | rs119103242 | c.1748N>A | p.Arg583His | p.R583H | P11498 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PC | SNV | Missense_Mutation | | c.1217G>A | p.Arg406His | p.R406H | P11498 | protein_coding | deleterious(0) | probably_damaging(0.985) | TCGA-C8-A138-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
PC | SNV | Missense_Mutation | | c.730N>T | p.His244Tyr | p.H244Y | P11498 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PC | SNV | Missense_Mutation | | c.1848N>A | p.Met616Ile | p.M616I | P11498 | protein_coding | deleterious(0.01) | benign(0.059) | TCGA-EW-A1PD-01 | Breast | breast invasive carcinoma | Male | <65 | I/II | Chemotherapy | docetaxel | SD |
PC | SNV | Missense_Mutation | novel | c.151N>A | p.Arg51Ser | p.R51S | P11498 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EW-A6SC-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | aromatase | SD |
PC | SNV | Missense_Mutation | | c.2395N>A | p.Asp799Asn | p.D799N | P11498 | protein_coding | tolerated(0.18) | probably_damaging(0.967) | TCGA-DS-A0VK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |